Patent: 10,517,947

Summary for Patent: 10,517,947

Title:	Methods for preparing squalene
Abstract:	An improved method for preparing squalene from a squalene-containing composition, said method comprising the steps of (a) a purification distillation carried out at a temperature T(b) a denaturing distillation carried out at a temperature T; wherein steps (a) and (b) may be performed in either order; Tand Tare sufficient to cause squalene to boil; T>T; and T>200° C.
Inventor(s):	Hora Maninder
Assignee:	NOVARTIS AG
Application Number:	US15842010
Patent Claims:	see list of patent claims

United States Patent 10,517,947: Claims, Validity Risks, and US Landscape

What does US 10,517,947 claim?

No claim text was provided in the prompt (the message ends at “The claims are:”). Without the actual claim language, a complete and accurate claim-by-claim analysis of scope, patentability, infringement-relevant elements, and freedom-to-operate filters cannot be produced.

What does the US patent landscape show around US 10,517,947?

No further bibliographic details, assignee, filing/priority dates, related continuations, examiner remarks, cited references, claim categories, or prosecution history were provided. Without those data, it is not possible to map the relevant US prior-art clusters, identify the most likely novelty/obviousness attack surfaces, or quantify competitive crowding (e.g., families with overlapping subject matter and remaining US term).

What are the key patentability pressure points?

A critical analysis requires at least:

• The independent claims and all dependent claims (exact wording).
• The effective filing date and priority chain.
• The specification support for claim limitations.
• The cited prior art and the examiner’s reasoning.

These inputs were not included, so the analysis cannot be completed.

What is the practical enforcement and FTO relevance?

FTO and enforcement relevance depend on:

• Claim construction levers (means-plus-function, functional limitations, range definitions, genus/species coverage).
• Territorial coverage (US claims only) and term status (expiration, PTA, terminal disclaimers).
• Likely design-arounds, at-issue dependent claim hooks, and competitor filings.

None of these are available in the prompt.

Key Takeaways

• US 10,517,947 cannot be analyzed at claim-level granularity because the claim text and core bibliographic/prosecution inputs were not provided.
• A landscape assessment (prior art, competitors, validity risks, and FTO posture) cannot be produced without the patent’s identifying details and the cited references.

FAQs

1. Can you analyze US 10,517,947 without the claim text?
   No. Claim scope, novelty and obviousness pressure points, and infringement-relevant elements require the exact claim language.

2. Can you map the prior-art and competitive landscape without bibliographic data?
   No. Landscape mapping depends on priority dates, family structure, and cited references from prosecution.

3. What inputs are necessary for a validity-risk analysis of the claims?
   Independent and dependent claim text, priority/effective filing dates, specification support for key limitations, and cited art with examiner reasoning.

4. How is FTO derived from a patent landscape?
   By aligning competitor products/processes to the claim elements and filtering out workable design-arounds using overlapping patent families and remaining term.

5. What typically drives the biggest uncertainty in claim construction for US patents?
   Functional or result-based limitations, broad genus claims with thin support, and definitional ambiguity in claim terms.

Sources (APA) [1] None provided in the prompt.

Details for Patent 10,517,947

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	August 31, 2005	10,517,947	2037-12-14
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	December 14, 2012	10,517,947	2037-12-14
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	October 05, 2006	10,517,947	2037-12-14
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	November 10, 2009	10,517,947	2037-12-14
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	August 15, 2013	10,517,947	2037-12-14

International Patent Family for US Patent 10,517,947

Country	Patent Number	Estimated Expiration
Australia	2011251706
Brazil	112012028711
Canada	2798924
China	102892734
China	105125488